Showing 4501-4510 of 9330 results for "".
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma aesthetics and correc…
- Ferndale Healthcare Launches Vegetarian Formula of Heliocarehttps://practicaldermatology.com/news/ferndale-healthcare-launches-vegetarian-formula-of-heliocare/2458868/Ferndale Healthcare® has introduced to its existing Heliocare® line a new vegetarian formula, free of gluten and artificial dyes. The new Heliocare® Ultra Dietary Supplement contains a powerful blend of antioxidants, including Fernblock® Polypodium leucotomos extract (PLE), Vitamin C, and Pomegrana…
- AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumabhttps://practicaldermatology.com/news/astrazeneca-and-valeant-pharmaceuticals-to-partner-on-brodalumab/2458881/AstraZeneca and Valeant Pharmaceuticals International, Inc. entered into a collaboration agreement under which AstraZeneca will grant Valeant an exclusive license to develop and commercialize brodalumab, an IL-17 receptor monoclonal antibody that is in development for patients with moderate-to-sev…
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determine the efficacy and safety of Rituxan for the treatment of PV. According to the company, results of independent studi…
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy1. “I have seen first-hand the deva…
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination with …
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) capsules, that are not covered by current FDA-approved labeling for the drug so long as …
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam compared to its foam vehicle (witho…
- National Psoriasis Foundation Launches Patient-centered Research Platformhttps://practicaldermatology.com/news/national-psoriasis-foundation-launches-patient-centered-research-platform/2458902/Patients with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation’s patient-centered research network called Citizen Pscientist. This online, interactive community, allows peop…
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medicinal Products f…